KRAS Wild-Type Pancreatic Cancer: Decoding Genomics, Unlocking Therapeutic Potential.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37695631.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2221 and PMC identifier 10872803.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers in these tumors, which holds the key to unlocking a realm of targeted therapies for patients with this understudied cancer subtype. See related article by Singh et al., p. 4627.
Medical subject headings
- Proto-Oncogene Proteins p21(ras)
- Pancreatic Neoplasms